Skip to main content
Enter your keywords
User account menu
Log in
Main navigation
About
History & Impact
Mission & Values
Leadership
Support SWOG
Join SWOG
Policies & Procedures
Careers
Contact Us
The SWOG Network
How We Work
Our Staff
Our Advocates
Our Partners
News & Events
News
SWOG Stories
SWOG Meetings
For Press
Clinical Trials
Biospecimen Submission
Biospecimen Access
Clinical Trials Search
Clinical Research Resources
Frequently Asked Questions
Publications
Institutions
Quality Assurance & Audits
Serious Adverse Events
Training Resources
CRA Workbench
Protocol Workbench
For Patients
Patient & Advocate Voices
Trials Open to Patients
About SWOG Cancer Trials
Joining a Trial
Glossary
Section navigation
Recent Updates
5/15/2024
5/1/2024
4/15/2024
4/1/2024
3/15/2024
3/1/2024
2/15/2024
2/1/2024
1/15/2024
1/1/2024
12/15/2023
12/1/2023
All Updates
Breadcrumb
SWOG
Member Resources
Trial & Business Updates
LungMAP
Priority List LungMAP
LUNGMAP
Other
A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
S1900E
II
A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
S1900K
II
A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
S1900G
II
A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)